Market Analysis and Sales Projections for Myorisan (Isotretinoin)
Overview of Myorisan
Myorisan, a brand of isotretinoin capsules, is a powerful medication used for the treatment of severe recalcitrant nodular acne. It is marketed by Akorn, Inc. under the VersaPharm label and is available in various strengths, including 10 mg, 20 mg, 30 mg, and 40 mg capsules[2].
Global Isotretinoin Drugs Market
The global isotretinoin drugs market, which includes Myorisan, has been experiencing significant growth. Here are some key points:
- Market Size: The global isotretinoin drugs market was valued at USD 1,337 million in 2022 and is projected to reach USD 2,053 million by 2031, growing at a CAGR of 4.88% during the forecast period[1].
- Regional Performance: North America is the largest market for isotretinoin drugs, driven by a well-developed healthcare infrastructure, favorable government regulations, and a high prevalence of skin problems. Europe is expected to grow at a CAGR of 3.84%, while the Asia-Pacific region is the fastest-growing market due to increasing awareness and the emergence of new players[1].
Sales Projections for Myorisan
Historical Sales Data
Historical data indicates that Myorisan has been a significant player in the isotretinoin market. For instance, sales of 10 mg, 20 mg, and 40 mg isotretinoin capsules were approximately $436 million for the twelve months ended July 31, 2015. The 30 mg strength, which was recently launched, added another $209 million in sales over the same period[2].
Future Growth
Given the overall growth trends in the isotretinoin market, Myorisan is likely to continue its upward sales trajectory. Here are some factors contributing to this growth:
- Increasing Prevalence of Acne: The rising prevalence of acne, especially among young adults, is a major driver. According to the Global Burden of Disease, acne vulgaris affects approximately 85% of young adults aged 12 to 25[1].
- Market Expansion: The expansion into emerging markets, particularly in the Asia-Pacific region, is expected to boost sales. Companies like Sun Pharma and Dr. Reddy's Laboratories Ltd in India are driving this growth[1].
- Regulatory Approvals and Awareness: Regulatory approvals and increased awareness campaigns are also contributing to the market growth. For example, the launch of new products and strengths, such as the 30 mg Myorisan capsules, has expanded the product portfolio and attracted more users[2].
Regional Market Performance
North America
North America remains the largest market for isotretinoin drugs, including Myorisan. This region benefits from a developed healthcare infrastructure, favorable government regulations, and a high prevalence of skin problems. The market in North America is anticipated to grow at a CAGR of 5.26% during the forecast period[1].
Europe
Europe is expected to grow at a CAGR of 3.84%, driven by rising cases of genetic disorders and skin cancer, a rapidly developing healthcare sector, and increasing healthcare spending. Critical players headquartered in Europe are innovating and driving growth in the regional market[1].
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for isotretinoin drugs. This growth is attributed to the emergence of many players, such as Sun Pharma and Dr. Reddy's Laboratories Ltd in India. The increasing awareness and demand for isotretinoin drugs in this region are expected to continue driving the market[1].
Key Drivers and Restraints
Drivers
- Rising Prevalence of Acne: The increasing prevalence of acne and other skin conditions is a primary driver of the market.
- Effectiveness of Isotretinoin: The effectiveness of isotretinoin in treating severe acne has led to its widespread adoption.
- Marketing and Awareness: Marketing and awareness campaigns have increased the visibility and demand for isotretinoin drugs.
- Regulatory Approvals: Regulatory approvals for new products and strengths have expanded the market[4].
Restraints
- Side Effects: Isotretinoin is known for its severe side effects, which can be a deterrent for some patients.
- Regulatory Scrutiny: The drug is under strict regulatory scrutiny, particularly in regions like the UK, where it can only be prescribed by a consultant dermatologist with experience in systemic retinoids[1].
Competitive Landscape
The isotretinoin market, including Myorisan, is competitive with several key players. Companies like Allergan, GALDERMA, and Bausch Health Companies Inc. are leading players in the global acne treatment market. Akorn, Inc., the manufacturer of Myorisan, competes in this landscape by offering a range of strengths and through strategic product launches[3].
Conclusion
Myorisan, as a part of the isotretinoin drugs market, is poised for significant growth driven by the increasing prevalence of acne, regulatory approvals, and expanding market presence in emerging regions. The drug's effectiveness and the launch of new strengths are key factors contributing to its sales projections.
Key Takeaways
- The global isotretinoin drugs market is projected to grow from USD 1,337 million in 2022 to USD 2,053 million by 2031.
- North America is the largest market, while the Asia-Pacific region is the fastest-growing.
- Myorisan sales are expected to grow due to the rising prevalence of acne and the effectiveness of the drug.
- Regulatory approvals and awareness campaigns are driving the market.
- The Asia-Pacific region is expected to see significant growth due to increasing awareness and the emergence of new players.
FAQs
What is Myorisan used for?
Myorisan is used for the treatment of severe recalcitrant nodular acne.
What are the different strengths of Myorisan available?
Myorisan is available in 10 mg, 20 mg, 30 mg, and 40 mg capsules.
Which region is the largest market for isotretinoin drugs?
North America is the largest market for isotretinoin drugs.
What is the projected growth rate of the global isotretinoin drugs market?
The global isotretinoin drugs market is projected to grow at a CAGR of 4.88% from 2022 to 2031.
What are the key drivers of the isotretinoin market?
The key drivers include the rising prevalence of acne, the effectiveness of isotretinoin, marketing and awareness campaigns, and regulatory approvals.
Sources
- Straits Research: Isotretinoin Drugs Market Size, Share, Analysis and Forecast to 2031
- BioSpace: Akorn, Inc. Launches Myorisan(TM) 30 mg Capsules
- Fortune Business Insights: Acne Treatment Market Size, Trends | Revenue Share [2032]
- The Business Research Company: Global Isotretinoin Drugs Market Report 2024
- Research Nester: Acne Medication Market Size | Growth Forecasts 2037
